Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: A pilot randomized placebo-controlled trial
2011

Methylphenidate for Treating Tobacco Dependence in Smokers

Sample size: 80 publication Evidence: low

Author Information

Author(s): Richard D Hurt, Jon O Ebbert, Ivana T Croghan, Darrell R Schroeder, Amit Sood, J Taylor Hays

Primary Institution: Mayo Clinic

Hypothesis

Can methylphenidate help non-ADHD smokers relieve nicotine withdrawal symptoms and promote smoking abstinence?

Conclusion

The study found no evidence that methylphenidate helps smokers quit or reduces withdrawal symptoms.

Supporting Evidence

  • Only 10% of the placebo group and 2.5% of the OROS-MPH group achieved smoking abstinence at the end of the medication phase.
  • Nicotine withdrawal symptoms did not significantly differ between the treatment groups.
  • Adverse events were reported more frequently in the OROS-MPH group compared to placebo.

Takeaway

The study tested a medicine called methylphenidate to see if it could help people stop smoking, but it didn't work.

Methodology

A randomized, double-blind, placebo-controlled, phase II study comparing methylphenidate to placebo over 8 weeks.

Potential Biases

Potential bias due to the high dropout rate and the specific population studied.

Limitations

The study had a high dropout rate and the sample may not represent all smokers.

Participant Demographics

Participants were adult cigarette smokers aged 18 to 65, mostly white, with a mean age of 37.3 years.

Statistical Information

P-Value

p = 0.464 for nicotine withdrawal symptoms, p = 0.786 for the first 14 days post-quit date.

Digital Object Identifier (DOI)

10.1186/1477-5751-10-1

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication